Enlivex Therapeutics Ltd
NASDAQ:ENLV

Watchlist Manager
Enlivex Therapeutics Ltd Logo
Enlivex Therapeutics Ltd
NASDAQ:ENLV
Watchlist
Price: 1.23 USD -0.81%
Market Cap: 27m USD
Have any thoughts about
Enlivex Therapeutics Ltd?
Write Note

Enlivex Therapeutics Ltd
Net Issuance of Common Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Enlivex Therapeutics Ltd
Net Issuance of Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
Enlivex Therapeutics Ltd
NASDAQ:ENLV
Net Issuance of Common Stock
$4.9m
CAGR 3-Years
-59%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
Collplant Biotechnologies Ltd
NASDAQ:CLGN
Net Issuance of Common Stock
$1.1m
CAGR 3-Years
-37%
CAGR 5-Years
-17%
CAGR 10-Years
N/A
Kamada Ltd
NASDAQ:KMDA
Net Issuance of Common Stock
$8k
CAGR 3-Years
-7%
CAGR 5-Years
-4%
CAGR 10-Years
N/A
Urogen Pharma Ltd
NASDAQ:URGN
Net Issuance of Common Stock
$170.1m
CAGR 3-Years
943%
CAGR 5-Years
0%
CAGR 10-Years
N/A
B
Bonus Biogroup Ltd
TASE:BONS
Net Issuance of Common Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pluri Inc
NASDAQ:PLUR
Net Issuance of Common Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Enlivex Therapeutics Ltd
Glance View

Market Cap
25.7m USD
Industry
Biotechnology

Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.

ENLV Intrinsic Value
1.18 USD
Overvaluation 4%
Intrinsic Value
Price

See Also

What is Enlivex Therapeutics Ltd's Net Issuance of Common Stock?
Net Issuance of Common Stock
4.9m USD

Based on the financial report for Jun 30, 2024, Enlivex Therapeutics Ltd's Net Issuance of Common Stock amounts to 4.9m USD.

What is Enlivex Therapeutics Ltd's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 5Y
-9%

Over the last year, the Net Issuance of Common Stock growth was 1 106%. The average annual Net Issuance of Common Stock growth rates for Enlivex Therapeutics Ltd have been -59% over the past three years , -9% over the past five years .

Back to Top